实用老年医学 ›› 2023, Vol. 37 ›› Issue (2): 128-133.doi: 10.3969/j.issn.1003-9198.2023.02.006

• 专题论坛 • 上一篇    下一篇

冠心平片治疗冠心病的Meta分析和序贯分析

嵇佳林, 刘晶, 王雪黎, 冯泓琳, 韩旭   

  1. 210029 江苏省南京市,南京中医药大学(嵇佳林);
    210029 江苏省南京市,南京中医药大学附属医院老年科(刘晶,王雪黎,冯泓琳,韩旭)
  • 收稿日期:2022-12-12 出版日期:2023-02-20 发布日期:2023-02-27
  • 通讯作者: 韩旭,Email:hanxu9998@126.com
  • 基金资助:
    江苏省自然科学基金资助项目(BK20181505);南京中医药大学中医学优势学科三期科研项目(ZYX03KF032);江苏省中医药科技发展专项计划(2020ZX08);江苏省卫生健康委员会老年医学临床技术应用研究项目带头人科研项目(LR2022002);2022年江苏省研究生实践创新计划(SJCX22_0766)

Ameta-analysis and sequential analysis of the effects of Guanxinping on coronary heart disease

JI Jia-lin, LIU Jing, WANG Xue-li, FENG Hong-lin, HAN Xu   

  1. Nanjing University of Chinese Medicine, Nanjing 210029, China(JI Jia-lin);
    Department of Geriatrics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China(LIU Jing, WANG Xue-li, FENG Hong-lin, HAN Xu)
  • Received:2022-12-12 Online:2023-02-20 Published:2023-02-27
  • Contact: HAN Xu, Email: hanxu9998@126.com

摘要: 目的 系统评价冠心平片治疗冠心病的临床疗效,以便为临床用药提供循证医学参考。方法 借助计算机对相关数据库展开检索,包括中国知网、Cochrane Library、维普、Embase、万方、CBM 与PubMed等,时间段为自建库起至2022年6月。由2位研究人员根据纳入标准独立甄选文献,对关于冠心平片治疗冠心病的随机对照试验(RCT)或病例对照组研究文献进行检索、资料收集。待文献筛选、资料提取结束,基于Cochrane系统评价员手册5.1.0中的偏倚风险评估工具对RCT文献进行质量评价。Meta分析工具为RevMan 5.3和Stata 15.0,运用TSA 0.9进行试验序贯分析,经由Stata 15.0来评估发表偏倚。结果 合计纳入25项研究,总样本量为1968例。Meta分析结果显示,冠心平片治疗冠心病在临床综合疗效(OR=2.78,95%CI:2.11~3.68)、心电图疗效(OR=2.63,95%CI:2.01~3.45)以及中医证候疗效(OR=3.27,95%CI:2.29~4.66)等方面均明显优于对照组。同时,试验序贯分析结果表明,冠心平片治疗冠心病临床疗效确切。结论 冠心平片治疗冠心病的临床疗效确切,具有临床价值。

关键词: 冠心平, 冠心病, Meta分析, 试验序贯分析

Abstract: Objective To systematically evaluate the clinical efficacy of Guanxinping on coronary heart disease(CHD),and provide evidence-based medicine basis for clinical medication. Methods The related literatures were searched in databases such as Chinese National Knowledge Infrastructure (CNKI), Cochrane Library, VIP, Embase, Wanfang database, China Biology Medicine (CBM),PubMed. The time limit was from the establishment of the database to June 2022.Two researchers independently selected literatures based on the inclusion criteria, and collected randomized controlled trials(RCT) and case-control studies of Guanxinping(the experimental group). After screening the literatures and extracting the data, the quality of RCTs were evaluated by the bias risk assessment tool recommended by Cochrane System Reviewer Manual 5.1.0. A Meta-analysis was performed by RevMan 5.3 and Stata 15.0. A trial sequential analysis was performed by TSA 0.9, and publication bias assessment was performed by Stata 15.0. Results A total of 25 studies were included, with a total sample of 1968 cases. The Meta-analysis results showed that the comprehensive clinical effect (OR=2.78,95%CI:2.11-3.68)、electrocardiogram curative effect (OR=2.63,95%CI:2.01-3.45) and traditional Chinese medicine(TCM) syndrome curative effect (OR=3.27,95%CI:2.29-4.66) of Guanxinping on CHD were significantly better than those in the control group. The sequential analysis of trials showed that the clinical total efficiency of Guanxinping on CHD was confirmed. Conclusions The clinical efficacy of Guanxinping on CHD is significant, and has potential value of clinical application.

Key words: Guanxinping, coronary heart disease, Meta-analysis, trial sequential analysis

中图分类号: